Can I Take Folate with Dayvigo (Lemborexant)?

How Dayvigo Works: A Quick Pharmacology Primer

Lemborexant blocks both orexin-1 (OX1R) and orexin-2 (OX2R) receptors, reducing wake-promoting signaling in the lateral hypothalamus. The FDA approved it in December 2019 at 5 mg and 10 mg doses for adults with insomnia characterized by difficulty with sleep onset or maintenance [1]. Unlike benzodiazepines or Z-drugs, DORAs do not act on GABA-A receptors.

CYP3A4-Driven Metabolism

Lemborexant undergoes oxidative metabolism primarily through cytochrome P450 3A4 (CYP3A4), with minor contributions from CYP3A5 [2]. This metabolic route matters for interaction screening: any supplement or drug that meaningfully inhibits or induces CYP3A4 can shift lemborexant plasma concentrations. Strong CYP3A4 inhibitors (ketoconazole, itraconazole) are contraindicated with Dayvigo, and moderate inhibitors require dose reduction to 5 mg [1].

Peak and Trough Timing

Lemborexant reaches peak plasma concentration (Tmax) in approximately 1 to 3 hours after oral dosing [2]. Its elimination half-life averages 17 to 19 hours, long enough that steady-state levels build over several days of nightly dosing. These kinetics are relevant when evaluating whether any co-administered supplement could alter absorption or clearance windows.

What Folate Does in the Body

Folate is the umbrella term for vitamin B9 in all its forms: dietary folate from leafy greens and legumes, synthetic folic acid used in fortified foods and supplements, and 5-methyltetrahydrofolate (5-MTHF), the biologically active circulating form [3]. The recommended dietary allowance (RDA) for adults is 400 mcg dietary folate equivalents (DFE) per day, rising to 600 mcg during pregnancy [4].

Methylation and One-Carbon Metabolism

Folate feeds into the one-carbon metabolism cycle, donating methyl groups for DNA synthesis, amino acid metabolism, and homocysteine remethylation to methionine [3]. Adequate folate status keeps plasma homocysteine in check. Elevated homocysteine (above 15 µmol/L) has been associated with cardiovascular risk in observational studies, though supplementation trials like HOPE-2 (N=5,522) showed reduced stroke incidence (risk ratio 0.75, 95% CI 0.59 to 0.97) without a significant reduction in overall cardiovascular mortality [5].

MTHFR Polymorphisms

The MTHFR C677T variant (homozygous TT genotype, present in roughly 10 to 15% of North American populations) reduces enzymatic conversion of folic acid to 5-MTHF by about 70% [6]. Individuals with this genotype often respond better to direct 5-MTHF supplementation (L-methylfolate) than to synthetic folic acid. This genetic consideration is relevant to folate form selection but does not affect lemborexant metabolism.

Is There a Pharmacokinetic Interaction?

No. The metabolic pathways of folate and lemborexant do not overlap in any clinically meaningful way.

Folate Does Not Touch CYP3A4

Folate is not metabolized by cytochrome P450 enzymes. It enters cells via folate receptors (FR-alpha, FR-beta) and the reduced folate carrier (RFC/SLC19A1), then undergoes polyglutamation for intracellular retention [7]. In vitro studies of common B vitamins have shown no inhibition of CYP3A4, CYP2D6, CYP1A2, or CYP2C9 at physiologically relevant concentrations [8]. The Natural Medicines Comprehensive Database rates folate as having no known interaction with orexin receptor antagonists [9].

No Transporter Competition

Lemborexant is a substrate of P-glycoprotein (P-gp) [2]. Folate uses distinct membrane transport proteins (RFC, PCFT/SLC46A1) and does not inhibit P-gp at supplemental doses [7]. There is no competition at the transporter level that would alter absorption of either compound.

Absorption Window Overlap Is Irrelevant

Because folate and lemborexant use independent absorption mechanisms, taking them at the same time does not create a meaningful interaction. Dayvigo is typically taken at bedtime, and folate can be taken at any time of day. No dose-separation window is pharmacologically required [1].

Is There a Pharmacodynamic Interaction?

Pharmacodynamic interactions occur when two agents act on the same receptor system or physiological pathway to produce additive or opposing effects. Folate and lemborexant operate in entirely separate domains.

No Shared Receptor Targets

Lemborexant targets OX1R and OX2R in the hypothalamus [1]. Folate participates in methylation biochemistry and has no direct receptor-mediated effect on sleep-wake circuitry. A 2020 cross-sectional analysis of NHANES data (N=13,432) found an association between low serum folate and short sleep duration, but the relationship was observational and did not imply a receptor-level mechanism [10].

Folate and Neurotransmitter Synthesis

Folate does contribute indirectly to neurotransmitter production. 5-MTHF is a cofactor in the synthesis of serotonin, dopamine, and norepinephrine via tetrahydrobiopterin (BH4) recycling [11]. L-methylfolate (marketed as Deplin at 15 mg) is FDA-cleared as a medical food for depression, adjunctive to SSRIs and SNRIs [12]. This indirect neurotransmitter support does not antagonize or potentiate orexin receptor blockade. The two mechanisms are pharmacodynamically independent.

What About Anticonvulsant Co-Use?

The brief mention of folate being "needed with anticonvulsants" raises an important clinical nuance. Some patients with insomnia also take anticonvulsants (valproate, carbamazepine, phenytoin) for comorbid epilepsy, mood disorders, or neuropathic pain. These drugs deplete folate stores through enzyme induction and altered folate metabolism [13].

Valproate and Folate Depletion

Valproate inhibits glutamate formyltransferase and other folate-dependent enzymes, lowering serum and red blood cell folate levels [13]. Women of reproductive age on valproate require folate supplementation of at least 1 mg daily (some guidelines recommend up to 5 mg) for neural tube defect prevention [14]. If a patient takes valproate, Dayvigo, and folate simultaneously, the relevant drug interaction exists between valproate and folate. Lemborexant is a bystander in this scenario.

Carbamazepine and CYP3A4 Induction

Carbamazepine is a strong CYP3A4 inducer, which creates a direct and significant interaction with lemborexant. Co-administration with strong CYP3A4 inducers is listed as a contraindication or avoidance in the Dayvigo label [1]. This interaction has nothing to do with folate. If you take carbamazepine and want to add Dayvigo, the conversation with your prescriber should focus on the CYP3A4 induction issue, not folate.

Practical Guidance: Taking Both Together

For most adults, combining folate supplementation with Dayvigo at bedtime requires no special adjustments. The following recommendations are based on the absence of interaction data and standard clinical practice.

Choosing Your Folate Form

If you have a confirmed MTHFR C677T homozygous (TT) genotype, L-methylfolate (5-MTHF) at 400 to 1,000 mcg daily may be preferable to folic acid, based on bioavailability data showing higher plasma folate levels with direct methylfolate supplementation in this population [6]. For individuals without MTHFR polymorphisms, standard folic acid at 400 to 800 mcg daily is adequate per NIH Office of Dietary Supplements guidelines [4].

Dosing Schedule

Take Dayvigo within 5 minutes of going to bed, as directed by FDA labeling [1]. Folate can be taken at any time. Morning dosing of folate is common and convenient, but taking it at bedtime alongside Dayvigo is also acceptable since no interaction exists.

Monitoring Recommendations

No additional laboratory monitoring is needed specifically because of the combination. Standard monitoring for each agent independently applies:

• For lemborexant: assess for next-day somnolence, sleep-related behaviors, and CNS depression, particularly in the first two weeks [1].
• For folate: if supplementing for a diagnosed deficiency or MTHFR variant, periodic serum folate and homocysteine levels are reasonable. A CBC can identify megaloblastic changes if deficiency was the initial indication [4].

When to Alert Your Prescriber

Contact your prescriber if you experience unusual daytime drowsiness, mood changes, or neurological symptoms (tingling, numbness). These are unlikely to result from a folate-lemborexant interaction but could indicate folate deficiency masking B12 deficiency, a well-documented clinical concern where high-dose folic acid corrects the anemia of B12 deficiency while allowing neurological damage to progress [15]. The Institute of Medicine set the tolerable upper intake level for folic acid at 1,000 mcg/day specifically to mitigate this masking risk [4].

Special Populations

Certain groups warrant additional consideration when using folate and Dayvigo together, though the considerations relate to each agent individually rather than a combined effect.

Pregnancy and Lactation

Lemborexant is not recommended during pregnancy due to insufficient human data, with animal studies showing adverse developmental effects at high doses [1]. Folate supplementation, by contrast, is strongly recommended at 400 to 800 mcg daily before and during early pregnancy per USPSTF Grade A recommendation for neural tube defect prevention [16]. If pregnancy is planned or discovered, the discussion should center on discontinuing Dayvigo and continuing folate.

Older Adults

The FDA-approved starting dose of lemborexant in older adults is 5 mg, the same as the general adult population, but clinicians should monitor for fall risk given the somnolence profile [1]. Folate requirements do not change with age (RDA remains 400 mcg DFE), though absorption may decrease with atrophic gastritis, present in an estimated 10 to 30% of adults over age 60 [4]. Neither of these age-related factors creates an interaction between the two agents.

Renal Impairment

No dose adjustment is required for lemborexant in mild to moderate renal impairment. Severe renal impairment has not been studied [2]. Folate is water-soluble and renally excreted; in chronic kidney disease (CKD), folate supplementation is common because dialysis removes folate, and elevated homocysteine is prevalent in CKD populations [17]. Again, no interaction between the two agents exists in this context.

What the Evidence Does Not Show

No published case reports, pharmacovigilance signals in the FDA Adverse Event Reporting System (FAERS), or entries in major interaction databases (Lexicomp, Micromedex, Natural Medicines) identify a folate-lemborexant interaction [9]. The absence of evidence is not proof of safety in every conceivable scenario, but it reflects a genuinely low-risk combination based on non-overlapping pharmacology.

A 2022 systematic review of orexin receptor antagonist drug interactions (covering suvorexant, lemborexant, and daridorexant) identified CYP3A4 modulators, CNS depressants, and alcohol as the primary interaction categories [18]. Vitamins and mineral supplements were not flagged in any of the reviewed studies.

Bottom Line

Folate and Dayvigo do not interact through any known pharmacokinetic or pharmacodynamic mechanism. Take your prescribed Dayvigo dose at bedtime and your folate supplement at whatever time is most convenient. If you carry an MTHFR variant, L-methylfolate may be a better folate form for you, but this decision is independent of Dayvigo use. The only scenario requiring extra attention is concurrent anticonvulsant therapy, where the relevant interactions involve the anticonvulsant, not the folate-Dayvigo pair. Standard monitoring for each agent applies: watch for next-day drowsiness with Dayvigo, and check serum folate and B12 if supplementing at doses above 400 mcg daily for extended periods [4][15].